ArticleFrontiers in immunology2022
5-Methylcytosine (m
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Systematic Review of Monocyte Transcriptomic Profiles as Diagnostic and Prognostic Biomarkers in Colorectal Cancer.International journal of molecular sciences · 2026Pooled it
- Role of m5C methylation in digestive system tumors (Review).Molecular medicine reports · 2025Pooled it
- mBiology direct · 2026Review
- Review
- 5-mC RNA methylation: a key regulator in cancer development and treatment.Journal of translational medicine · 2026Review
- RNA Methylation in Cancer Metabolism: from Mechanisms to Therapeutic Opportunities.International journal of biological sciences · 2026Review
- Multifaceted functions of Y‑box binding protein 1 in RNA methylated modifications (Review).Molecular medicine reports · 2025Review
- The Role of NSUN Family Genes in m5C Methylation and Diseases.Biomedicines · 2025Review
- NSUN5 Mediates Resistance to Doxorubicin via Up-regulation of DNA Damage Repair Proteins BRCA2 and BRIP1 in Colorectal Cancer.The American journal of pathology · 2025Article
- m5C RNA modification in colorectal cancer: mechanisms and therapeutic targets.Journal of translational medicine · 2025Review
- Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance.Signal transduction and targeted therapy · 2025Review
- Research on RNA modification in disease diagnosis and prognostic biomarkers: current status and challenges.Briefings in bioinformatics · 2025Review
- Detection, molecular function and mechanisms of m5C in cancer.Clinical and translational medicine · 2025Review
- The Role of Epigenetic Mechanisms in the Treatment of GI Cancers.Current cancer drug targets · 2025Review
- Epitranscriptomic mechanisms and implications of RNA mTheranostics · 2025Review
- Dysregulation of tRNA methylation in cancer: Mechanisms and targeting therapeutic strategies.Cell death discovery · 2024Review
- Extracellular vesicles-derived CXCL4 is a candidate serum tumor biomarker for colorectal cancer.iScience · 2024Article
- Development of m6A/m5C/m1A regulated lncRNA signature for prognostic prediction, personalized immune intervention and drug selection in LUAD.Journal of cellular and molecular medicine · 2024Article
- Multi-omic analyses of m5C readers reveal their characteristics and immunotherapeutic proficiency.Scientific reports · 2024Article
- m5C methylation modification may be an accomplice in colorectal cancer escaping from anti-tumor effects of innate immunity-type I/III interferon.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current non-invasive tumor biomarkers failed to accurately identify patients with colorectal cancer (CRC), delaying CRC diagnosis and thus leading to poor prognosis. Dysregulation of 5-Methylcytosine (m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.